Table 2.

Phase I clinical trial targeting survivin for advanced and recurrent colorectal cancer (15 patients)

Vaccination	Survivin2B 80-88 (AYACNTSTL) peptide alone is given every 14 days for a total of six times
Toxicities	Three patients demonstrated toxicities: anemia (grade 2), general malaise (grade 1), and fever (grade 1)
Surrogate marker response	Six patients showed temporary decreased in CEA and CA 19-9 levels during the time of vaccination
Tumor volume	One patient demonstrated minor tumor reduction.
Immunologic response	In one patient, HLA-A24/peptide tetramer demonstrated increased CTL response against survivin 2B peptide from 0.09 to 0.35% of CD8+ T cells after four vaccinations